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Abstract
Background: The CyberKnife is an appealing delivery system for hypofractionated stereotactic body radiation
therapy (SBRT) because of its ability to deliver highly conformal radiation therapy to moving targets. This
conformity is achieved via 100s of non-coplanar radiation beams, which could potentially increase transitory
testicular irradiation and result in post-therapy hypogonadism. We report on our early experience with CyberKnife
SBRT for low- to intermediate-risk prostate cancer patients and assess the rate of inducing biochemical and clinical
hypogonadism.
Methods: Twenty-six patients were treated with hypofractionated SBRT to a dose of 36.25 Gy in 5 fractions. All
patients had histologically confirmed low- to intermediate-risk prostate adenocarcinoma (clinical stage ≤ T2b,
Gleason score ≤ 7, PSA ≤ 20 ng/ml). PSA and total testosterone levels were obtained pre-treatment, 1 month post-
treatment and every 3 months thereafter, for 1 year. Biochemical hypogonadism was defined as a total serum
testosterone level below 8 nmol/L. Urinary and gastrointestinal toxicity was assessed using Common Toxicity
Criteria v3; quality of life was assessed using the American Urological Association Symptom Score, Sexual Health
Inventory for Men and Expanded Prostate Cancer Index Composite questionnaires.
Results: All 26 patients completed the treatment with a median 15 months (range, 13-19 months) follow-up.
Median pre-treatment PSA was 5.75 ng/ml (range, 2.3-10.3 ng/ml), and a decrease to a median of 0.7 ng/ml (range,
0.2-1.8 ng/ml) was observed by one year post-treatment. The median pre-treatment total serum testosterone level
was 13.81 nmol/L (range, 5.55 - 39.87 nmol/L). Post-treatment testosterone levels slowly decreased with the
median value at one year follow-up of 10.53 nmol/L, significantly lower than the pre-treatment value (p < 0.013).
The median absolute fall was 3.28 nmol/L and the median percent fall was 23.75%. There was no increase in
biochemical hypogonadism at one year post-treatment. Average EPIC sexual and hormonal scores were not
significantly changed by one year post-treatment.
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Conclusions: Hypofractionated SBRT offers the radiobiological benefit of a large fraction size and is well-tolerated
by men with low- to intermediate-risk prostate cancer. Early results are encouraging with an excellent biochemical
response. The rate of new biochemical and clinical hypogonadism was low one year after treatment.
Background
Recent analyses of clinical data suggest that large radia-
tion fraction sizes are radiobiologically favorable com-
pared to smaller fraction sizes in prostate cancer
radiotherapy [1]. The CyberKnife (Accuray, Inc., Sunny-
vale, CA) is an FDA-approved radiosurgical device that
is ideal for accurately delivering hypofractionated stereo-
tactic body radiation therapy (SBRT) [2]. Treatment is
delivered by a linear accelerator mounted on a flexible
robotic arm. A few hundred treatment beams are
selected from a repertoire of greater than one thousand
possible beam directions using inverse treatment plan-
ning. These beams are delivered in a non-isocentric,
non-coplanar manner via circular collimators of varying
sizes. Access to a large number of potential beam trajec-
tories allows delivery of a highly conformal dose with
steep dose gradients [3,4]. Unlike standard radiation
therapy delivery systems, the CyberKnife system incor-
porates a dynamic tracking system consisting of an
orthogonal pair of diagnostic-quality x-ray imaging
devices and software that can locate fiducials implanted
within the prostate [5]. This provides updated position
information in six dimensions (three translations com-
bined with roll, pitch and yaw rotations) [6] to the
robot, which adjusts the targeting of the therapeutic
beam during treatment to correct for intra-fraction
motion. These features allow for a reduction in the
planning target volume (PTV) and potentially the dose
to surrounding critical organs. These technical improve-
ments should allow for dose escalation within the pros-
tate while maintaining normal tissue tolerance.
The early efficacy and safety of CyberKnife hypofrac-
tionated dose-escalated SBRT have been documented
for localized treatment of prostate cancer [7-9]. Stan-
ford’s phase II protocol delivered 36.25 Gy in 5 fractions
of 7.25 Gy. This dose and fractionation were selected
for radiobiologic dose escalation while keeping a con-
stant predicted normal tissue late effect. In King et al.’s
report on 41 “low-risk” patients, at a median of 33
months after treatment, the mean PSA was 0.44 ng/ml
[7], suggesting a high rate of long-term control [10]. No
patient experienced grade 4 toxicity, and only two
patients experienced grade 3 late urinary morbidity.
Similar results with similar regimens have been reported
by others [8,9].
Due to anatomic proximity, the testes are at risk for
exposure to scattered radiation during prostate treat-
ment. It has been suggested that the non-coplanar
nature of CyberKnife SBRT may increase the risk of tes-
ticular irradiation during treatment [11]. The resulting
decline in testosterone levels [12,13] could be responsi-
ble for the low PSA nadirs [14] obtained with Cyber-
Knife SBRT. If so, the post-treatment PSA response may
not accurately reflect the likelihood of long-term tumor
control with such treatment [10]. Equally important, the
resulting endocrine changes may contribute to post-
radiation hypogonadism with subsequent depression,
cognitive decline, decreased libido and impotence [15].
Knowledge of the relative risks of hypogonadism due to
available treatment options for prostate cancer could
affect patients’ treatment decisions. In this paper, we
report on the use of CyberKnife SBRT as monotherapy
for the treatment of 26 prostate cancer patients and
show that the risk of new biochemical and clinical hypo-
gonadism is low within the first year after treatment.
Methods
Patient Selection
Patients eligible for inclusion in this study had histologi-
cally-confirmed low- to intermediate-risk adenocarci-
noma of the prostate (clinical stage ≤ T2b, Gleason
score ≤ 7, PSA ≤ 20 ng/ml). Exclusion criteria included
androgen deprivation therapy, clinically involved lymph
nodes on imaging, distant metastases on bone scan,
prior pelvic radiotherapy or prior radical prostate sur-
gery. Institutional IRB approval was obtained for this
retrospective review.
SBRT Treatment Planning and Delivery
Four gold fiducials were placed into the prostate prior to
treatment planning: two at the apex and two at the base.
To allow for fiducial stabilization, planning imaging was
performed at least 7 days after fiducial placement.
Patients underwent 1.5 T MR imaging followed shortly
thereafter by a thin-cut (1.25 mm) CT scan. Both scans
were performed with an empty bladder. Patients were
advised to adhere to a low-fiber diet, starting at least
five days prior to all treatment planning imaging and
treatment delivery. They were restricted to nothing by
mouth (NPO) the night before, and an enema was admi-
nistered 1-2 hours prior to imaging and treatment.
Fused CT and MR images were used for treatment
planning (Figure 1). The gross target volume (GTV) was
the prostate. The clinical target volume (CTV) included
the prostate and the proximal seminal vesicles to the
point where the left and right seminal vesicles separate.
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The PTV equaled the CTV expanded 3 mm posteriorly
and 5 mm in all other dimensions. The prescription
dose was 36.25 Gy to the PTV delivered in five fractions
of 7.25 Gy over two weeks. The volume of the PTV
receiving 36.25 Gy was at least 95%. The prescription
isodose line was limited to ≥ 75%, which limited the
maximum prostatic urethra dose to 133% of the pre-
scription dose. The rectum, bladder, testes, penile bulb
and membranous urethra were contoured structures and
evaluated with dose-volume histogram analysis during
treatment planning using Multiplan (Accuray Inc., Sun-
nyvale, CA) inverse treatment planning. Rectal volume
receiving 36 Gy was limited to < 1 cc. The rectal dose-
volume histogram (DVH) goals were < 50% rectal
volume receiving 50% of the prescribed dose, < 20%
receiving 80% of the dose, < 10% receiving 90% of the
dose, and < 5% receiving 100% of the dose [7]. The
empty bladder volume receiving 37 Gy was limited to <
10 cc [8]. Care was taken to avoid treatment beams that
directly traversed the testes, and the scatter dose was
kept to a minimum. Image-guidance was employed to
minimize the required PTV treatment margins. Using
computed tomography planning, target volume locations
were related to the gold fiducial markers. Position verifi-
cation was validated several times per minute during
treatment using paired, orthogonal, and x-ray images.
Follow-up
PSA and total testosterone levels were obtained before
treatment, one month after the completion of radiation,
and during routine follow-up visits every 3 months for
the first year. Samples were obtained in the morning
and early afternoon to limit the effects of circadian var-
iation [16]. Biochemical hypogonadism was defined as
total serum testosterone level below 8 nmol/L [17].
Toxicity was assessed pre-treatment and at 1, 3, 6, 9
and 12 months post-treatment using the National Can-
cer Institute (NCI) Common Toxicity Criteria (CTC)
version 3.0 [18] and the American Urological Associa-
tion (AUA) symptom score (also known as International
Prostate Symptom Score) [19]. Quality of life (QoL) was
assessed pre-treatment and at follow-up visits using the
Short Form-12 Health Survey (SF-12), the Expanded
Prostate Cancer Index Composite (EPIC) [20] and the
Sexual Health Inventory for Men (SHIM) [21].
Statistical Analysis
Skewed continuous variables, e.g., testosterone and PSA,
were described as the sample median and range. Catego-
rical variables were described as frequency and percen-
tage. Obtaining PSA, total testosterone, and quality of
life measurements sequentially in each patient constitu-
tes a natural control for potentially wide baseline varia-
tion across patients. Therefore responses to radiotherapy
were assessed using non-parametric pairwise Wilcoxon
rank-sum testing [22].
Results
From January 2009 to June 2009, 26 prostate cancer
patients were treated per our institutional protocol.
Their median age was 69 years (range, 48-79 years).
Similar numbers of Caucasians and African-Americans
were enrolled reflecting the distribution of our patient
population. Fourteen patients were low-risk, and 12
patients were intermediate-risk per the D’Amico Risk
Classification [23]. Table 1 provides detailed patient
characteristics.
At a median follow-up of 15 months (range, 13-19
months), the initial PSA response has been favorable,
with decreased PSA levels in all patients. The median
pre-treatment PSA was 5.75 ng/ml (range, 2.3-10.3 ng/
ml); it decreased to a median of 0.7 ng/ml (range, 0.2-
1.8 ng/ml) by one year post-treatment (Figure 2A), sug-
gesting a high rate of long term disease control using
this treatment regimen [24].
Consistent with our elderly patient population, pre-
treatment total serum testosterone levels were low, ran-
ging from 5.55 nmol/L to 39.87 nmol/L with a median
value of 13.81 nmol/L[25]. The median testicular scatter
dose was 2.1 Gy (range, 1.1-5.8 Gy). Post-treatment
total serum testosterone levels fell in 18 patients (69%)
and increased in 8 patients (31%). At one year the med-
ian serum testosterone value of 10.53 nmol/L (range,
5.79-22.38 nmol/L) was significantly lower than the
pre-treatment value (p < 0.013) (Figure 2B). The median
absolute fall was small (3.28 nmol/L) and the median
percent fall was 23.75%. Pre- and post-treatment median
total testosterone levels are shown in Figure 2B. In con-
trast to the total serum testosterone levels, the PSA to
testosterone ratio decreased in all the patients, suggest-
ing that the PSA decrease was not due solely to the
drop in testosterone (Figure 2C). Based on the
Figure 1 Treatment planning axial (A) and sagittal (B)
computed tomography images demonstrating the GTV (red),
CTV and PTV expansion (dark blue), bladder (orange), rectum
(green), bowel (yellow), membranous urethra (pink) and penile
bulb (light blue). Isodose lines shown as follows: Blue 79%
(prescription), white 70% and purple 50%.
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International Society for the Study of the Aging Male
(ISSAM) definition (< 8 nmol/L) [18], the pre-treatment
and 1-year biochemical hypogonadism rates were identi-
cal (Figure 3).
Toxicity has been minimal with no Grade 3 or higher
gastrointestinal (GI) or gastrourinary (GU) toxicities
(Table 2). Grade 1 and 2 acute toxicities included urin-
ary symptoms requiring alpha blockers and bowel fre-
quency/spasms requiring antidiarrheals. At one year
post-treatment, the patients’ perceptions of their physi-
cal (Figure 4A) and mental health (Figure 4B) were
unchanged (Table 3). At one month post-treatment the
mean AUA toxicity increased to 10.8 from a baseline of
6.8 (p = 0.0001), and the mean EPIC urinary score
decreased to 82.7 from a baseline 90.5 (p = 0.0001), see
Figures 5A and 5B and Table 3. Both mean AUA and
EPIC urinary scores returned to baseline by one year
after treatment. At one month post-treatment, the mean
EPIC bowel score declined to 91.7 from a baseline of
95.7 (p = 0.042) (see Figure 5C and Table 3) and
returned to baseline by one year after treatment.
Sexual dysfunction is a major criterion for the clinical
diagnosis of hypogonadism [26]. At one year post-treat-
ment, the mean SHIM decreased to 14.3 from a baseline
of 17.2, and the mean EPIC sexual scores decreased to
60.1 from a baseline of 66.7 (Figures 6A and 6B, Table
3). However, these changes were small and not statisti-
cally (p = 0.126 and p = 0.341, respectively) or clinically
significant [27]. At one month post-treatment, the mean
EPIC hormone score declined to 90.9 from a baseline of
94.2 (p = 0.039); it returned to baseline by one year
post-treatment (Figure 6C and Table 3).
Discussion
Pelvic irradiation causes a dose-dependent reduction in
serum testosterone levels that increases with larger field
sizes and higher testicular doses [28]. For conventional
pelvic radiation therapy, the drop is approximately 10-
30%; this reaches a nadir, on average, several months
post-treatment and can persist for years thereafter
[28-33]. In addition to precipitating clinical hypogonad-
ism, with its adverse effects [15], this testosterone
Table 1 Pre-treatment patient characteristics
# Age Race PSA (ng/mL) T Stage Gleason Score Risk Group Prostate Volume (cc) AUA SHIM
1 60 Cau 4.7 1c 3+3 Low 53 3 20
2 69 Cau 6.8 1c 3+4 Intermediate 46 3 14
3 69 Cau 6.1 1c 3+3 Low 29 9 1
4 60 Cau 4.5 1c 3+3 Low 21 3 18
5 71 AA 4.0 1c 2+3 Low 31 16 19
6 72 Cau 5.6 1c 3+3 Low 41 4 1
7 56 AA 5.7 1c 3+3 Low 43 9 16
8 70 Cau 4.9 1c 3+3 Low 23 4 21
9 74 Cau 4.9 1c 3+3 Low 45 10 15
10 78 Cau 8.1 2b 3+3 Intermediate 33 1 3
11 71 Cau 4.9 1c 3+3 Low 33 5 20
12 58 AA 7.9 1c 3+4 Intermediate 37 12 21
13 66 Cau 10.3 1c 3+3 Intermediate 34 14 25
14 74 AA 6.3 1c 4+3 Intermediate 55 9 4
15 70 Cau 6.8 1c 3+3 Low 30 21 20
16 62 Cau 4.0 1c 3+4 Intermediate 30 1 25
17 79 Cau 2.3 2b 3+4 Intermediate 52 5 3
18 48 AA 6.8 1c 3+3 Low 18 8 24
19 73 Cau 6.9 1c 3+4 Intermediate 40 3 4
20 62 Cau 5.6 1c 3+3 Low 25 6 23
21 63 AA 6.2 1c 3+4 Intermediate 42 4 15
22 69 AA 5.8 1c 3+4 Intermediate 42 6 18
23 71 AA 5.9 1c 3+3 Low 34 2 24
24 65 Cau 7.4 1c 4+3 Intermediate 33 7 24
25 78 AA 4.2 2b 4+3 Intermediate 37 10 1
26 67 Cau 4 2a 3+3 Low 49 5 20
Abbreviations: Cau - Caucasian; AA - African American; AUA - American Urology Association; SHIM - sexual health inventory for men.
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decline may undermine the utility of PSA as a tumor
response marker [10]. Radiation dose escalation, hypo-
fractionation, and the increased total body radiation
with multi-field treatments [34] and image guidance
[35] could enhance this testosterone decline. Thus, this
study was aimed to assess the risk of biochemical and
clinical hypogonadism following CyberKnife SBRT
monotherapy for clinically localized prostate cancer.
In our study, we observed a small decline (23.75%) in
total testosterone levels after SBRT treatment consistent
with that reported by others [36] and similar to that
seen with conventional prostate radiation therapy [30].
This decline in testosterone was unlikely responsible for
a promising 12-month PSA nadir as variations in serum
testosterone do not greatly affect PSA levels in eugona-
dal men [37,38]. It remains to be determined whether
testosterone decreases are temporary or permanent as
these levels can take years to normalize [28]. Future stu-
dies will determine if testosterone levels fully recover to
age-appropriate levels in our patient population.
The cause of this testosterone decline is unknown.
Leydig cell dysfunction due to testicular scatter irradia-
tion (mean dose of 2-4 Gy) in older men has been pro-
posed as the major causative factor [12,29,31-33].
However, normal age-related testosterone decline [25]
and treatment related stress [39] may also contribute.
To determine if emotional and physiological stress
could be responsible for our small decline in total tes-
tosterone, we examined acute toxicity and quality of life
indicators. Acute Grade 2 GU and GI toxicities were
observed in 27% and 0% of patients, respectively (Table
2). There were no Grade 3 or higher acute toxicities.
These results appear comparable to other published
external beam radiation therapy series [19,40,41]. In the
opinion of the authors, it is unlikely that these minimal
toxicities were responsible for the observed decline in
serum testosterone. Consistent with findings of others,
the small decline in total testosterone had minimal
effects on quality of life [42]. Our AUA, SHIM and
Figure 2 Pre- and post-treatment (A) PSA levels, (B) total
testosterone levels, and (C) PSA/testosterone ratios for all
patients. Error bars indicate 95% confidence intervals.
Figure 3 Comparison of pre-treatment biochemical
hypogonadism rates to those at up to 1 year following
treatment.
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Figure 4 Short Form-12 (SF-12) Health Survey quality of life:
(A) SF-12 physical component score (PCS) and (B) SF-12 mental
component score (MCS). The graphs show unadjusted changes in
average scores over time. The scores range from 0 - 100 with
higher values representing improved health status. Numbers above
each time point indicate the number of observations contributing
to the average.
Table 2 Summary of CTC graded acute gastrointestinal
(GI) and genitourinary (GU) toxicities
Gastrointestinal Pre-Tx 1 Month 3 Month 6 Month
Toxicity Grade N % N % N % N %
Diarrhea 0 21 (81) 19 (73) 21 (81) 20 (77)
1 5 (19) 7 (27) 5 (19) 6 (23)
2 0 (0) 0 (0) 0 (0) 0 (0)
Proctitis 0 26 (100) 22 (85) 23 (88) 24 (92)
1 0 (0) 4 (15) 3 (12) 2 (8)
2 0 (0) 0 (0) 0 (0) 0 (0)
Rectal 0 25 (96) 25 (96) 25 (96) 25 (96)
Bleeding 1 1 (4) 1 (4) 1 (4) 1 (4)
2 0 (0) 0 (0) 0 (0) 0 (0)
Highest GI 0 20 (77) 16 (62) 19 (73) 19 (73)
1 6 (23) 10 (38) 7 (27) 7 (27)
2 0 (0) 0 (0) 0 (0) 0 (0)
Pre-Tx 1 Month 3 Month 6 Month
Toxicity Grade N % N % N % N %
Hematuria 0 26 (100) 26 (100) 26 (100) 26 (100)
1 0 (0) 0 (0) 0 (0) 0 (0)
2 0 (0) 0 (0) 0 (0) 0 (0)
Dysuria 0 22 (85) 17 (65) 25 (96) 25 (96)
1 4 (15) 9 (35) 1 (4) 1 (4)
2 0 (0) 0 (0) 0 (0) 0 (0)
Incontinence 0 25 (96) 18 (69) 19 (73) 21 (81)
1 1 (4) 7 (27) 7 (27) 5 (19)
2 0 (0) 1 (4) 0 (0) 0 (0)
Urinary 0 26 (100) 23 (88) 23 (88) 23 (88)
Freq/Urg 1 0 (0) 3 (12) 3 (12) 3 (12)
2 0 (0) 0 (0) 0 (0) 0 (0)
Retention 0 14 (54) 5 (19) 9 (35) 8 (31)
1 12 (46) 14 (54) 10 (38) 12 (46)
2 0 (0) 7 (27) 7 (27) 6 (23)
Highest GU 0 13 (50) 5 (19) 7 (27) 8 (31)
1 13 (50) 14 (54) 12 (46) 12 (46)
2 0 (0) 7 (27) 7 (27) 6 (23)
2 0 (0) 0 (0) 0 (0) 0 (0)
Table 3 Overview of patient quality of life (QoL)
Pre-Treatment 1 Month 3 Month 6 Month 9 Month 12 Month
SF-12 PCS 50 (35.2 - 58.9) 50.9 (31.4 - 61.4) 50.5 (31.4 - 61.2) 50.6 (25.7 - 56.7) 49 (27.1 - 57.2) 49 (27.6 - 59.8)
SF-12 MCS 54.8 (37.2 - 61.3) 54.4 (41.2 - 61) 55.2 (37.3 - 63.2) 55.7 (34.5 - 61.5) 57 (47.1 - 64.7) 56.5 (38.5 - 62.6)
AUA 6.8 (1 - 21) 10.8 (3 - 20) 8.1 (1 - 21) 7.7 (1 - 23) 7.5 (2 - 26) 7.4 (0 - 22)
SHIM 17.2 (3 - 25) 16 (1 - 25) 15 (1 - 25) 15.2 (1 - 25) 15.6 (1 - 25) 14.3 (1 - 25)
EPIC Urinary 90.5 (63 - 100) 82.7 (61.1 - 100) 87.7 (53.7 - 100) 88.5 (65.8 - 100) 88.1 (68.6 - 100) 89 (60.2 - 100)
EPIC Bowel 95.7 (66.7 - 100) 91.7 (62.5 - 100) 92.6 (66.7 - 100) 94.1 (70.8 - 100) 94.1 (62.5 - 100) 94.8 (75 - 100)
EPIC Sexual 66.7 (27.8 - 95.8) 66.4 (20.8 - 100) 59.9 (0 - 100) 59.8 (0 - 100) 60 (16.7 - 100) 60.1 (13.8 - 100)
EPIC Hormonal 94.2 (75 - 100) 90.9 (70 - 100) 90.8 (60 - 100) 92.3 (60 - 100) 93.6 (60 - 100) 92.1 (60 - 100)
The table shows unadjusted changes in mean toxicity and QOL scores over time. SF-12 scores range from 0 - 100 with higher values representing improved
health status. AUA scores range from 0 - 35 with higher values representing worsening urinary symptoms. SHIM scores range from 0 - 25 with lower values
representing worsening sexual function. EPIC scores range from 0 - 100 with higher values representing a more favorable health-related QOL. Bolded items
signify a statistically significant change in reported QoL from baseline measured by Wilcoxon rank sum test at 0.05 significance level.
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Figure 5 Urinary and bowel quality of life using the American
Urology Association (AUA) score and the Expanded Prostate
Cancer Index Composite (EPIC): (A) AUA score, (B) EPIC urinary
and (C) EPIC bowel. The graphs show unadjusted changes in
average scores over time for each domain. AUA scores range from
0 - 35 with higher values representing worsening urinary symptoms.
EPIC scores range from 0 - 100 with higher values representing a
more favorable health-related QOL. Numbers above each time point
indicate the number of observations contributing to the average.
Error bars indicate 95% confidence intervals.
Figure 6 Sexual quality of life using the Health Inventory for
Men (SHIM) and Expanded Prostate Cancer Index Composite
(EPIC): (A) SHIM, (B) EPIC sexual and (C) EPIC hormonal scores.
The graphs show unadjusted changes in average scores over time
for each domain. SHIM scores range from 0 - 25 with lower values
representing worsening sexual symptoms. EPIC scores range from 0
- 100 with higher values representing a more favorable health-
related QOL. The graphs show unadjusted changes in average
toxicity and QOL scores over time. Numbers above each time point
indicate the number of observations contributing to the average.
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EPIC scores returned to baseline by one year after treat-
ment (Table 3 and Figures 5 and 6). This is not unex-
pected as a total testosterone of 8 nmol/L is likely
adequate for normal physiologic and sexual functioning
[18]. Whatever the cause, the small decline in total tes-
tosterone does not appear to be clinically significant as
it did not adversely affect the utility of the PSA as a
measure of tumor response or induced clinical
hypogonadism.
Conclusions
Hypofractionated SBRT is a promising new treatment
option for men with low- and intermediate-risk prostate
cancer. Early results suggest encouraging biochemical
response with low toxicity and a low rate of new bio-
chemical and clinical hypogonadism one year after treat-
ment Investigation of more patients with longer follow-
up is required to validate these conclusions.
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